A jury finds NCAA is not to blame in lawsuit over football player’s death after repeated head trauma
LOS ANGELES — In a verdict that could affect countless claims by athletes who sue…
Category: neurology
.jpg)
World Cup: Concussion protocol in Iran-England match was “utter disgrace,” says charity
The brain injury charity Headway has condemned the decision to allow Iran’s goalkeeper, Alireza Beiranvand,…
STAT+: Triplet Therapeutics, biotech company focused on Huntington’s, quietly shuts down
A biotech company co-founded by venture capital firm Atlas Venture has shut down after running…
STAT+: Alzheimer’s clinical trials have a recruitment problem. Telehealth platform Ro thinks it can help
Telehealth company Ro has reached an agreement with the National Institute on Aging to create…
An Alzheimer’s therapy scores winning results, but what could it mean for patients?
The news Tuesday night that a clinical trial of an experimental Alzheimer’s therapy had succeeded…
Daily multivitamins improved the brain function of seniors in a trial — but plenty of questions remain
While pharma companies struggle to show that cutting-edge therapies can treat, prevent, or slow Alzheimer’s…
Opinion: Listen: A doctor with ALS laments the slow pace for drug approval
During his long career as a pediatric oncologist and cancer researcher, William Woods thought highly…
STAT+: How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy
So, imagine you get punched in the head. Not once, but a bunch of times….
In early research, an AI model detects signs of Parkinson’s using breathing patterns
James Parkinson first flagged a link between changes in breathing patterns and the debilitating disease…
Zapping the brain with electricity shown to boost older people’s short- and long-term memory
Sending weak electrical current into the brain for 20 minutes a day for four days…
New research finds blood tests can predict severe outcomes of brain injury
Simple blood tests taken on the day of a traumatic brain injury (TBI) can predict…
Colin Blakemore: neuroscientist who explored the symbiotic relation between art and science
bmj;378/aug02_12/o1910/FAF1faCredit: David Hartley, ShutterstockColin Blakemore made an outstanding contribution to understanding of vision and neural…
STAT+: FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results
The Food and Drug Administration has agreed to review a treatment for a rare, genetically…
STAT+: FDA to convene second panel of outside experts to review Amylyx Pharma’s ALS treatment
Amylyx Pharmaceuticals said Tuesday that the Food and Drug Administration is bringing together a panel…
STAT+: Can Biogen’s backup plan for Alzheimer’s succeed?
Everyone needs a backup plan, including one of the biggest biotech companies in town. So…
STAT+: Cognito Therapeutics raises $50 million for Alzheimer’s treatment tech
Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for…
Opinion: The often-overlooked connection between traumatic brain injury and domestic violence
Traumatic brain injury, long linked to military service and sports, has another more insidious source:…
The brain ‘learns’ to have seizures more efficiently and frequently over time, mouse study shows
Calculus. Ballroom dancing. The words to your favorite song. There’s practically no limit to what…
Opinion: Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?
On March 30, an FDA advisory panel voted 6 to 4 against recommending approval of…
STAT+: ‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval
Whither accelerated approval? Amid the hubbub over new Medicare coverage restrictions for Alzheimer’s treatments, a…
With pharma still struggling in Alzheimer’s, health tech companies want a swing
In the wake of the first Alzheimer’s drug approval in nearly two decades, pharmaceutical companies…
.jpg)
With new ‘brain-reading’ research, a once-tarnished scientist seeks redemption
Niels Birbaumer, once a prominent neuroscientist at the University of Tübingen in Germany, fell hard…
Before Aduhelm, Billy Dunn was a superstar at the FDA
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: An ALS therapy sets up a crucial test of the FDA’s independence
WASHINGTON — A high-profile, experimental therapy for ALS is teeing up a crucial test of…
Virtual Event: ‘Augmented’: The future of brain-controlled prosthetic limbs
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET…
STAT+: 4 epilepsy-focused biotech companies to watch
More companies than ever before are training their sights on developing treatments for epilepsy, which…
STAT+: Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s
Flagship Pioneering is gearing up to launch a new company that seems to be developing…
STAT+: Acadia drug meets endpoints for treating Rett syndrome, a rare neurological disease
An experimental drug being developed by Acadia Pharmaceuticals improved the symptoms of women and girls…
STAT+: Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial
Cortexyme, pressing forward after its novel approach to Alzheimer’s disease failed in a mid-stage trial,…
New study revives a Mozart sonata as a potential epilepsy therapy
Could this be the return of the “Mozart effect”? In 1993, researchers reported that after…
‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues
It’s been two weeks since Lisa Stockman Mauriello passed away and a lingering question, in…
STAT+: Veterans Affairs declines to cover Biogen Alzheimer’s drug over effectiveness and safety concerns
The Department of Veterans Affairs has decided not to cover a new Alzheimer’s drug from…
Dementia risk in professional footballers is linked to player position and career length, study finds
The risk of neurodegenerative disease in former professional footballers varies by the position they play…
STAT+: Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say
If ever there were a cautionary tale for the Food and Drug Administration’s approval of…
STAT+: Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits
A prominent panel of medical experts unanimously voted that there is no evidence to suggest…
STAT+: ‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug
Though a rival’s Alzheimer’s drug reached the market first, the CEO of Eli Lilly spoke…
STAT+: Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug
A majority of U.S. physicians disagree with the decision by the Food and Drug Administration…
STAT+: Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s drugs?
In an unexpected move, U.S regulators granted Eli Lilly (LLY) a breakthrough designation for its…
A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?
For families and physicians grappling with the historic approval this month of the controversial Alzheimer’s…
STAT+: Poll: Many Americans concerned about FDA approval process for Alzheimer’s drug
Two-thirds of Americans who are familiar with the details of the newly approved Alzheimer’s treatment…
STAT+: ‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval
Reacting to the controversial approval of the Biogen (BIIB) Alzheimer’s drug, a leading advocacy group…
Opinion: 6 ways the FDA’s approval of Aduhelm does more harm than good
Like many people, I was shocked when the Food and Drug Administration ignored the advice…
‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients
Their phones are ringing off the hook and their email inboxes are filling up with…
STAT+: Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s
WASHINGTON — The Food and Drug Administration fast-tracked Biogen’s divisive Alzheimer’s drug Aduhelm, but it’s…
STAT+: What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead
Despite all the excitement surrounding the FDA’s approval on Monday of a controversial treatment for Alzheimer’s disease, the…
STAT+: The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price
When Amber Freed heard in 2020 that a drug might help save her young child…
STAT+: Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year
The controversial, but widely anticipated Biogen (BIIB) treatment for Alzheimer’s would only be cost-effective if…
Biogen to expand access to its ALS drug, but move may come too late for some patients
After weeks of controversy, Biogen (BIIB) has agreed to provide an experimental drug for combating…
Covid-19 gave scientists an opening to better understand how brain disorders arise
While the Covid-19 pandemic put many human research studies on hold, neuroscientist Grainne McAlonan of…
A new crop of medical devices are trying to hack the vagus nerve to treat disease
The vagus nerve, also known as the “wandering nerve,” winds a path all around your…